Hengrui and Kailera’s Obesity Drug HRS9531 Shows Promising Results in Phase 2 Trial
Clinical Trial Results:
The Phase 2 clinical trial of HRS9531, a GLP-1/GIP receptor dual agonist, demonstrated a statistically significant mean weight loss of 22.8% (21.1% placebo-adjusted) at 36 weeks. 59% of participants achieved a weight loss of ≥20%13.
Safety Profile:
The trial showed a favorable safety profile with most adverse events being mild and consistent with the profile reported for injectable GLP-1/GIP receptor dual agonists13.
Comparison with Zepbound:
The results place HRS9531 in a similar efficacy range as Zepbound (tirzepatide), which showed a 20.2% average weight loss in a head-to-head trial against Wegovy (semaglutide)25.
Development Status:
Hengrui Pharmaceuticals and Kailera Therapeutics are advancing HRS9531 (also known as KAI-9531) into a global Phase 3 program for chronic weight management13.
Mechanism of Action:
HRS9531 is a dual-agonist drug, affecting both GLP-1 and GIP receptors, similar to Zepbound, which is also a dual-agonist drug14.
Sources:
1. https://www.biospace.com/press-releases/jiangsu-hengrui-pharmaceuticals-and-kailera-therapeutics-report-positive-topline-data-from-8-mg-dose-of-phase-2-obesity-trial-of-glp-1-gip-receptor-dual-agonist-hrs9531
2. https://investor.lilly.com/news-releases/news-release-details/lillys-zepboundr-tirzepatide-superior-wegovyr-semaglutide-head
3. https://www.kailera.com/press-release/jiangsu-hengrui-pharmaceuticals-and-kailera-therapeutics-report-positive-topline-data-from-8-mg-dose-of-phase-2-obesity-trial-of-glp-1-gip-receptor-dual-agonist-hrs9531/
4. https://www.baptisthealth.com/blog/weight-management/zepbound-vs-ozempic-what-are-the-differences